Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of P-Cresol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.44 |
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 2/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | RECQL | P46063 | 2/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.56 |
| ▸ | THRB | P10828 | 2/20 | 0.56 |
| ▸ | CASP1 | P29466 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 4/20 | 0.52 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 3/20 | 0.48 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| P-Cresol SCHEMBL31258814 | 1.00 | ACHE (0.72) | ACHEALDH1A1HPGDALOX15HSD17B10 | |
| P-Cresol SCHEMBL28950342 | 0.97 | ACHE (0.68) | ACHEALDH1A1HPGDALOX15HSD17B10 | |
| P-Xylene SCHEMBL2456088 | 0.88 | GAA (0.58) | ACHEALDH1A1CYP3A4LMNAGAA | |
| P-Xylene SCHEMBL27791681 | 0.88 | GAA (0.58) | ACHEALDH1A1CYP3A4LMNAGAA | |
| P-Cresol SCHEMBL11808203 | 0.85 | ACHE (0.59) | ACHEALDH1A1HPGDALOX15HSD17B10 | |
| Hydroquinone SCHEMBL7614409 | 0.85 | LMNA (0.77) | ACHEALDH1A1LMNAENPP2GAA | |
| Phenolsulfonic Acid SCHEMBL21551817 | 0.85 | LMNA (0.77) | ACHEALDH1A1LMNAENPP2GAA | |
| P-Cresol SCHEMBL28898083 | 0.85 | LMNA (0.77) | ACHEALDH1A1LMNAENPP2GAA | |
| P-Xylene SCHEMBL2020013 | 0.85 | GAA (0.55) | ACHEALDH1A1CYP3A4LMNAGAA | |
| P-Xylene SCHEMBL27484841 | 0.85 | GAA (0.55) | ACHEALDH1A1CYP3A4LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 876 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3869192-B1 | METHOD FOR QUANTITATIVE DETECTION OF VARIOUS METABOLITES IN BIOLOGICAL SAMPLE | HUMAN METABOLOMICS INST INC (CN) | 2026-05-13 | — | — | EP | claimed |
| EP-4701438-A1 | COMPOSITIONS AND METHODS FOR IMPROVING METABOLIC HEALTH | Société des Produits Nestlé S.A. (CH) | 2026-03-04 | — | — | EP | claimed |
| US-20260009800-A1 | METHODS OF DIAGNOSIS AND GUIDING TREATMENT OF VULVOVAGINAL SYMPTOMS AND FEMALE SEXUAL DYSFUNCTION | UNIV ARIZONA (US) | 2026-01-08 | — | — | US | claimed |
| US-12517140-B2 | Biomarkers for predicting intensive care unit stay duration for mechanically ventilated covid-19 patients | QATAR UNIVERSITY (QA) | 2026-01-06 | — | — | US | claimed |
| US-20250258146-A1 | QUANTITATIVE DETECTION METHOD OF MULTIPLE METABOLITES IN BIOLOGICAL SAMPLE AND METABOLIC CHIP | HUMAN METABOLOMICS INSTITUTE INC. (CN) | 2025-08-14 | — | — | US | claimed |
| WO-2025123045-A1 | PREDICTIVE AND DIAGNOSTIC SCREENING METHODS FOR ENDOMETRIAL CANCER | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2025-06-12 | — | — | WO | claimed |
| CN-120064627-A | Biomarker for diagnosing parkinsonism accompanied with rapid eye movement and sleep behavior disorder and application thereof | 上海健康医学院 | 2025-05-30 | — | — | CN | claimed |
| US-12292445-B2 | Methods of selecting subjects for treatment with metabolomic modulators | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-05-06 | — | — | US | claimed |
| CN-119804680-A | Method and kit for detecting intestinal microbial metabolites in biological sample | 南方医科大学珠江医院 | 2025-04-11 | — | — | CN | claimed |
| CN-119534874-A | Metabolic marker for auxiliary diagnosis of schizophrenia, construction method and application | 驻马店市第二人民医院(驻马店市精神病医院) | 2025-02-28 | — | — | CN | claimed |
| US-20130052172-A1 | METHODS FOR DIAGNOSING AND TREATING CARDIAC DEFECTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-02-28 | — | — | US | claimed |
| CN-102497774-A | Methods of assessing embryo outcome | BWT BIOMETRICS LLC | 2012-06-13 | — | — | CN | claimed |
| EP-2453738-A1 | METHODS OF ASSESSING EMBRYO OUTCOME | BWT Biometrics, LLC (US) | 2012-05-23 | — | — | EP | claimed |
| US-20120123193-A1 | METHOD OF ASSESSING EMBRYO OUTCOME | BWT BIOMETRICS, LLC (US) | 2012-05-17 | — | — | US | claimed |
| WO-2011008932-A1 | METHODS OF ASSESSING EMBRYO OUTCOME | MOLECULAR BIOMETRICS, INC. (US) | 2011-01-20 | — | — | WO | claimed |
| EP-2164977-A2 | BIOMARKERS FOR PRE-DIABETES, CARDIOVASCULAR DISEASES, AND OTHER METABOLIC-SYNDROME RELATED DISORDERS AND METHODS USING THE SAME | Metabolon Inc. (US) | 2010-03-24 | — | — | EP | claimed |
| US-20090155826-A1 | Biomarkers for pre-diabetes, cardiovascular diseases, and other metabolic-syndrome related disorders and methods using the same | METABOLON, INC. (US) | 2009-06-18 | — | — | US | claimed |
| WO-2009014639-A2 | BIOMARKERS FOR PRE-DIABETES, CARDIOVASCULAR DISEASES, AND OTHER METABOLIC-SYNDROME RELATED DISORDERS AND METHODS USING THE SAME | METABOLON, INC. (US) | 2009-01-29 | — | — | WO | claimed |
| US-6284473-B1 | P-cresol sulfate, a component of urinary myelin basic protein-like material, as a correlate of multiple sclerosis status | UAB RESEARCH FOUNDATION | 2001-09-04 | — | — | US | claimed |
| WO-2001025787-A1 | p-CRESOL SULFATE, A COMPONENT OF URINARY MYELIN BASIC PROTEIN-LIKE MATERIAL, AS A CORRELATE OF MULTIPLE SCLEROSIS STATUS | UAB RESEARCH FOUNDATION (US) | 2001-04-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260009800-A1 | METHODS OF DIAGNOSIS AND GUIDING TREATMENT OF VULVOVAGINAL SYMPTOMS AND FEMALE SEXUAL DYSFUNCTION | SHBG, GNRHR, STIM2 | MAOA 1957/4885MAOB 1896/4885ACHE 1702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.